JPWO2019136168A5

JPWO2019136168A5 -

Info

Publication number: JPWO2019136168A5
Application number: JP2020537006A
Authority: JP
Publication date: 2022-01-14
Anticipated expiration: 2039-01-03

Description

本特許のファイルは、カラーで実行される少なくとも１つの図面を含む。カラー図面を有する本特許のコピーは、要求および必要な手数料の納付により、特許商標庁によって提供される。
特定の実施形態では、例えば以下の項目が提供される。
（項目１）
ａ）
ｉ）グルコースを含み痙攣を示す新生仔患者；および
ｉｉ）グルコースオキシダーゼを含む組成物
を用意するステップ；ならびに
ｂ）前記痙攣が低減されるような条件下で、前記組成物を前記患者に投与するステップを含む、方法。
（項目２）
前記条件が、前記グルコースのグルコネートへの変換を含む、項目１に記載の方法。
（項目３）
前記組成物が、薬学的に許容される組成物である、項目１に記載の方法。
（項目４）
前記投与するステップが、有効量の前記組成物をさらに含む、項目１に記載の方法。 The file of this patent contains at least one drawing performed in color. A copy of this patent with color drawings is provided by the Patent and Trademark Office upon request and payment of the required fees.
In certain embodiments, for example, the following items are provided.
(Item 1)
a)
i) Neonatal patients with glucose and convulsions; and
ii) Composition containing glucose oxidase
Steps to prepare;
b) A method comprising administering the composition to the patient under conditions such that the spasm is reduced.
(Item 2)
The method of item 1, wherein the conditions include the conversion of glucose to gluconate.
(Item 3)
The method of item 1, wherein the composition is a pharmaceutically acceptable composition.
(Item 4)
The method of item 1, wherein the administration step further comprises an effective amount of the composition.

Claims

Use of a composition comprising glucose oxidase for the manufacture of a pharmaceutical product for treating neonatal seizures in a subject requiring treatment of neonatal seizures.

The use according to claim 1, wherein the composition converts glucose to gluconate in the subject in need of treatment of neonatal seizures.

An oral pharmaceutical composition comprising glucose oxidase and supplemental glucose, CLC-3 Cl upregulated compared to non-neonatal babies. ^－- An oral pharmaceutical composition that acts to reduce convulsive activity in neonates with channels.

The oral pharmaceutical composition of claim 3, wherein the newborn has circulating glucose.

The oral pharmaceutical composition according to claim 4, wherein the glucose oxidase converts the circulating glucose into gluconate.

The gluconate is the CLC-3 Cl ^－- The oral pharmaceutical composition of claim 5, which inhibits the channel.

The CLC-3 Cl ^－- The oral pharmaceutical composition of claim 6, wherein inhibition of the channel reduces the convulsive activity in the newborn.

The oral pharmaceutical composition according to claim 3, wherein the newborn is diagnosed with neonatal epilepsy.

The oral pharmaceutical composition of claim 3, wherein the newborn is less than 1 month old.

The oral pharmaceutical composition of claim 3, further comprising a pharmaceutically acceptable carrier.

A pharmaceutical formulation for use as a drug in the treatment of convulsive activity in newborns, a fixed dose of CLC-3 Cl ^－- A pharmaceutical formulation comprising a channel inhibitor, supplemental glucose and an inert carrier.

The CLC-3 Cl ^－- The pharmaceutical preparation according to claim 11, wherein the channel inhibitor is glucose oxidase.

The pharmaceutical preparation according to claim 11, wherein the inert carrier is a saline solution.

The pharmaceutical preparation according to claim 12, wherein the newborn baby has circulating glucose, and the glucose oxidase converts the circulating glucose into gluconate.

12. The pharmaceutical formulation of claim 12, wherein the supplemental glucose and the glucose oxidase are administered to the newborn at the fixed dose of a glucose infusion rate of 7.3 mg / kg / min.

The pharmaceutical preparation according to claim 15, wherein the administration is by intravenous injection.

The newborn has been diagnosed with neonatal epilepsy, or the newborn has been upregulated compared to a non-newborn CLC-3 Cl. ^－- The pharmaceutical preparation according to claim 11, which has a channel.

The pharmaceutical preparation according to claim 11, which is administered to the newborn baby by a transdermal patch.

A composition comprising glucose oxidase for the treatment of neonatal seizures in a subject in need of treatment of neonatal seizures.